Loading…
2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential
Purpose Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential. Methods A working group performed a systematic literature review using Medline, Embase, and Scopus databases between June 201...
Saved in:
| Published in: | Supportive care in cancer 2024-01, Vol.32 (1), p.37-37, Article 37 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c403t-c51a83d92cc68165f0a5a862f7cb502426d32fa22d5b96e47b1ef88171dd9d4e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c403t-c51a83d92cc68165f0a5a862f7cb502426d32fa22d5b96e47b1ef88171dd9d4e3 |
| container_end_page | 37 |
| container_issue | 1 |
| container_start_page | 37 |
| container_title | Supportive care in cancer |
| container_volume | 32 |
| creator | Olver, Ian Clark-Snow, Rebecca Ruhlmann, Christina H. Garcia-del-Barrio, Maria-Angeles Schwartzberg, Lee Rapoport, Bernardo Leon Jahn, Franziska |
| description | Purpose
Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential.
Methods
A working group performed a systematic literature review using Medline, Embase, and Scopus databases between June 2015 and January 2023 of the management of antiemetic prophylaxis for anticancer therapy of low or minimal emetic potential. A consensus committee reviewed recommendations and required a consensus of 67% or greater and a change in outcome of at least 10%.
Results
Of 293 papers identified, 15 had information about managing systemic cancer treatment regimens of low or minimal emetic potential and/or compliance with previous management recommendations. No new evidence was reported that would change the current MASCC recommendations. No antiemetic prophylaxis is recommended for minimal emetic potential therapy, and single agents recommended for low emetic potential chemotherapy for acute emesis, but no prophylaxis is recommended for delayed emesis. Commonly, rescue medication includes antiemetics prescribed for the next higher level of emesis.
Conclusion
There is insufficient data to change the current guidelines. Future studies should seek to more accurately determine the risk of emesis with LEC beyond the emetogenicity of the chemotherapy to include patient-related risk assessment. |
| doi_str_mv | 10.1007/s00520-023-08223-2 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2903860333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A776740116</galeid><sourcerecordid>A776740116</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-c51a83d92cc68165f0a5a862f7cb502426d32fa22d5b96e47b1ef88171dd9d4e3</originalsourceid><addsrcrecordid>eNp9kcFu1DAURS0EotOBH2CBLLFhE_psx3HCbjQqBalVF4W15bFfZlIl9mA7rfoF_DaeTqESC7ywpffOvbryJeQdg08MQJ0lAMmhAi4qaHm5-QuyYLUQlRKie0kW0NWsqoWUJ-Q0pVsAppTkr8mJaBkD2bIF-cWLnM57ZzI6erW6Wa_Pzm-urqkNPqFPc6IRbZgm9AUZyvDzYZVjGMfBb6k3c0JDjXf0LkxDPszuh7yjdodTyDuMZv9AQ0_HcE9DpNPgh8mMFCfMg6X7kNHnwYxvyKvejAnfPr1L8uPL-ff11-ry-uLbenVZ2RpErqxkphWu49Y2LWtkD0aatuG9shsJvOaNE7w3nDu56Rqs1YZh37ZMMec6V6NYko9H330MP2dMWU9DsjiOxmOYk-YdiLYBUc6SfPgHvQ1z9CXdI8VYLQGeqa0ZUQ--DzkaezDVK6UaVQNjTaH4kbIxpBSx1_tY_iE-aAb6UKY-lqlLG_qxTM2L6P1TgHkzofsr-dNeAcQRSGXltxifE_7H9jeBeakc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2903114500</pqid></control><display><type>article</type><title>2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential</title><source>Social Science Premium Collection</source><source>Springer Nature</source><source>Sociology Collection</source><creator>Olver, Ian ; Clark-Snow, Rebecca ; Ruhlmann, Christina H. ; Garcia-del-Barrio, Maria-Angeles ; Schwartzberg, Lee ; Rapoport, Bernardo Leon ; Jahn, Franziska</creator><creatorcontrib>Olver, Ian ; Clark-Snow, Rebecca ; Ruhlmann, Christina H. ; Garcia-del-Barrio, Maria-Angeles ; Schwartzberg, Lee ; Rapoport, Bernardo Leon ; Jahn, Franziska</creatorcontrib><description>Purpose
Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential.
Methods
A working group performed a systematic literature review using Medline, Embase, and Scopus databases between June 2015 and January 2023 of the management of antiemetic prophylaxis for anticancer therapy of low or minimal emetic potential. A consensus committee reviewed recommendations and required a consensus of 67% or greater and a change in outcome of at least 10%.
Results
Of 293 papers identified, 15 had information about managing systemic cancer treatment regimens of low or minimal emetic potential and/or compliance with previous management recommendations. No new evidence was reported that would change the current MASCC recommendations. No antiemetic prophylaxis is recommended for minimal emetic potential therapy, and single agents recommended for low emetic potential chemotherapy for acute emesis, but no prophylaxis is recommended for delayed emesis. Commonly, rescue medication includes antiemetics prescribed for the next higher level of emesis.
Conclusion
There is insufficient data to change the current guidelines. Future studies should seek to more accurately determine the risk of emesis with LEC beyond the emetogenicity of the chemotherapy to include patient-related risk assessment.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-023-08223-2</identifier><identifier>PMID: 38110581</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antiemetics ; Antiemetics - therapeutic use ; Antineoplastic Agents - adverse effects ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical practice guidelines ; Consensus ; Disease prevention ; Emetics ; Humans ; Medical colleges ; Medicine ; Medicine & Public Health ; Nausea ; Nausea - chemically induced ; Nausea - drug therapy ; Nausea - prevention & control ; Nursing ; Nursing Research ; Oncology ; Pain Medicine ; Palonosetron ; Practice Guidelines as Topic ; Rehabilitation Medicine ; Side effects ; Special Section ; Systematic Reviews as Topic ; Vomiting ; Vomiting - chemically induced ; Vomiting - drug therapy ; Vomiting - prevention & control</subject><ispartof>Supportive care in cancer, 2024-01, Vol.32 (1), p.37-37, Article 37</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>COPYRIGHT 2024 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-c51a83d92cc68165f0a5a862f7cb502426d32fa22d5b96e47b1ef88171dd9d4e3</citedby><cites>FETCH-LOGICAL-c403t-c51a83d92cc68165f0a5a862f7cb502426d32fa22d5b96e47b1ef88171dd9d4e3</cites><orcidid>0000-0001-5570-154X ; 0000-0001-7610-3653 ; 0000-0002-7433-3428 ; 0000-0002-3728-273X ; 0000-0001-5478-1576</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2903114500/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2903114500?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,21393,21394,27923,27924,33610,33611,34529,34530,43732,44114,74092,74510</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38110581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Olver, Ian</creatorcontrib><creatorcontrib>Clark-Snow, Rebecca</creatorcontrib><creatorcontrib>Ruhlmann, Christina H.</creatorcontrib><creatorcontrib>Garcia-del-Barrio, Maria-Angeles</creatorcontrib><creatorcontrib>Schwartzberg, Lee</creatorcontrib><creatorcontrib>Rapoport, Bernardo Leon</creatorcontrib><creatorcontrib>Jahn, Franziska</creatorcontrib><title>2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Purpose
Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential.
Methods
A working group performed a systematic literature review using Medline, Embase, and Scopus databases between June 2015 and January 2023 of the management of antiemetic prophylaxis for anticancer therapy of low or minimal emetic potential. A consensus committee reviewed recommendations and required a consensus of 67% or greater and a change in outcome of at least 10%.
Results
Of 293 papers identified, 15 had information about managing systemic cancer treatment regimens of low or minimal emetic potential and/or compliance with previous management recommendations. No new evidence was reported that would change the current MASCC recommendations. No antiemetic prophylaxis is recommended for minimal emetic potential therapy, and single agents recommended for low emetic potential chemotherapy for acute emesis, but no prophylaxis is recommended for delayed emesis. Commonly, rescue medication includes antiemetics prescribed for the next higher level of emesis.
Conclusion
There is insufficient data to change the current guidelines. Future studies should seek to more accurately determine the risk of emesis with LEC beyond the emetogenicity of the chemotherapy to include patient-related risk assessment.</description><subject>Antiemetics</subject><subject>Antiemetics - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical practice guidelines</subject><subject>Consensus</subject><subject>Disease prevention</subject><subject>Emetics</subject><subject>Humans</subject><subject>Medical colleges</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nausea</subject><subject>Nausea - chemically induced</subject><subject>Nausea - drug therapy</subject><subject>Nausea - prevention & control</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Pain Medicine</subject><subject>Palonosetron</subject><subject>Practice Guidelines as Topic</subject><subject>Rehabilitation Medicine</subject><subject>Side effects</subject><subject>Special Section</subject><subject>Systematic Reviews as Topic</subject><subject>Vomiting</subject><subject>Vomiting - chemically induced</subject><subject>Vomiting - drug therapy</subject><subject>Vomiting - prevention & control</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ALSLI</sourceid><sourceid>HEHIP</sourceid><sourceid>M2R</sourceid><sourceid>M2S</sourceid><recordid>eNp9kcFu1DAURS0EotOBH2CBLLFhE_psx3HCbjQqBalVF4W15bFfZlIl9mA7rfoF_DaeTqESC7ywpffOvbryJeQdg08MQJ0lAMmhAi4qaHm5-QuyYLUQlRKie0kW0NWsqoWUJ-Q0pVsAppTkr8mJaBkD2bIF-cWLnM57ZzI6erW6Wa_Pzm-urqkNPqFPc6IRbZgm9AUZyvDzYZVjGMfBb6k3c0JDjXf0LkxDPszuh7yjdodTyDuMZv9AQ0_HcE9DpNPgh8mMFCfMg6X7kNHnwYxvyKvejAnfPr1L8uPL-ff11-ry-uLbenVZ2RpErqxkphWu49Y2LWtkD0aatuG9shsJvOaNE7w3nDu56Rqs1YZh37ZMMec6V6NYko9H330MP2dMWU9DsjiOxmOYk-YdiLYBUc6SfPgHvQ1z9CXdI8VYLQGeqa0ZUQ--DzkaezDVK6UaVQNjTaH4kbIxpBSx1_tY_iE-aAb6UKY-lqlLG_qxTM2L6P1TgHkzofsr-dNeAcQRSGXltxifE_7H9jeBeakc</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Olver, Ian</creator><creator>Clark-Snow, Rebecca</creator><creator>Ruhlmann, Christina H.</creator><creator>Garcia-del-Barrio, Maria-Angeles</creator><creator>Schwartzberg, Lee</creator><creator>Rapoport, Bernardo Leon</creator><creator>Jahn, Franziska</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5570-154X</orcidid><orcidid>https://orcid.org/0000-0001-7610-3653</orcidid><orcidid>https://orcid.org/0000-0002-7433-3428</orcidid><orcidid>https://orcid.org/0000-0002-3728-273X</orcidid><orcidid>https://orcid.org/0000-0001-5478-1576</orcidid></search><sort><creationdate>20240101</creationdate><title>2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential</title><author>Olver, Ian ; Clark-Snow, Rebecca ; Ruhlmann, Christina H. ; Garcia-del-Barrio, Maria-Angeles ; Schwartzberg, Lee ; Rapoport, Bernardo Leon ; Jahn, Franziska</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-c51a83d92cc68165f0a5a862f7cb502426d32fa22d5b96e47b1ef88171dd9d4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antiemetics</topic><topic>Antiemetics - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical practice guidelines</topic><topic>Consensus</topic><topic>Disease prevention</topic><topic>Emetics</topic><topic>Humans</topic><topic>Medical colleges</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nausea</topic><topic>Nausea - chemically induced</topic><topic>Nausea - drug therapy</topic><topic>Nausea - prevention & control</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Pain Medicine</topic><topic>Palonosetron</topic><topic>Practice Guidelines as Topic</topic><topic>Rehabilitation Medicine</topic><topic>Side effects</topic><topic>Special Section</topic><topic>Systematic Reviews as Topic</topic><topic>Vomiting</topic><topic>Vomiting - chemically induced</topic><topic>Vomiting - drug therapy</topic><topic>Vomiting - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olver, Ian</creatorcontrib><creatorcontrib>Clark-Snow, Rebecca</creatorcontrib><creatorcontrib>Ruhlmann, Christina H.</creatorcontrib><creatorcontrib>Garcia-del-Barrio, Maria-Angeles</creatorcontrib><creatorcontrib>Schwartzberg, Lee</creatorcontrib><creatorcontrib>Rapoport, Bernardo Leon</creatorcontrib><creatorcontrib>Jahn, Franziska</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olver, Ian</au><au>Clark-Snow, Rebecca</au><au>Ruhlmann, Christina H.</au><au>Garcia-del-Barrio, Maria-Angeles</au><au>Schwartzberg, Lee</au><au>Rapoport, Bernardo Leon</au><au>Jahn, Franziska</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>32</volume><issue>1</issue><spage>37</spage><epage>37</epage><pages>37-37</pages><artnum>37</artnum><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Purpose
Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential.
Methods
A working group performed a systematic literature review using Medline, Embase, and Scopus databases between June 2015 and January 2023 of the management of antiemetic prophylaxis for anticancer therapy of low or minimal emetic potential. A consensus committee reviewed recommendations and required a consensus of 67% or greater and a change in outcome of at least 10%.
Results
Of 293 papers identified, 15 had information about managing systemic cancer treatment regimens of low or minimal emetic potential and/or compliance with previous management recommendations. No new evidence was reported that would change the current MASCC recommendations. No antiemetic prophylaxis is recommended for minimal emetic potential therapy, and single agents recommended for low emetic potential chemotherapy for acute emesis, but no prophylaxis is recommended for delayed emesis. Commonly, rescue medication includes antiemetics prescribed for the next higher level of emesis.
Conclusion
There is insufficient data to change the current guidelines. Future studies should seek to more accurately determine the risk of emesis with LEC beyond the emetogenicity of the chemotherapy to include patient-related risk assessment.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38110581</pmid><doi>10.1007/s00520-023-08223-2</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5570-154X</orcidid><orcidid>https://orcid.org/0000-0001-7610-3653</orcidid><orcidid>https://orcid.org/0000-0002-7433-3428</orcidid><orcidid>https://orcid.org/0000-0002-3728-273X</orcidid><orcidid>https://orcid.org/0000-0001-5478-1576</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2024-01, Vol.32 (1), p.37-37, Article 37 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2903860333 |
| source | Social Science Premium Collection; Springer Nature; Sociology Collection |
| subjects | Antiemetics Antiemetics - therapeutic use Antineoplastic Agents - adverse effects Cancer Cancer therapies Care and treatment Chemotherapy Clinical practice guidelines Consensus Disease prevention Emetics Humans Medical colleges Medicine Medicine & Public Health Nausea Nausea - chemically induced Nausea - drug therapy Nausea - prevention & control Nursing Nursing Research Oncology Pain Medicine Palonosetron Practice Guidelines as Topic Rehabilitation Medicine Side effects Special Section Systematic Reviews as Topic Vomiting Vomiting - chemically induced Vomiting - drug therapy Vomiting - prevention & control |
| title | 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T18%3A58%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=2023%20updated%20MASCC/ESMO%20consensus%20recommendations:%20controlling%20nausea%20and%20vomiting%20with%20chemotherapy%20of%20low%20or%20minimal%20emetic%20potential&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Olver,%20Ian&rft.date=2024-01-01&rft.volume=32&rft.issue=1&rft.spage=37&rft.epage=37&rft.pages=37-37&rft.artnum=37&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-023-08223-2&rft_dat=%3Cgale_proqu%3EA776740116%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c403t-c51a83d92cc68165f0a5a862f7cb502426d32fa22d5b96e47b1ef88171dd9d4e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2903114500&rft_id=info:pmid/38110581&rft_galeid=A776740116&rfr_iscdi=true |